Total body irradiation plus fludarabine compared to busulfan plus fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

Autor: Giebel, S, Labopin, M, Sobczyk-Kruszelnicka, M, Stelljes, M, Byrne, JL, Fegueux, N, Beelen, DW, Rovira, M, Spyridonidis, A, Blaise, D, Bornhauser, M, Karadogan, I, Savani, BN, Nagler, A, Mohty, M, Martin, S, Chevallier, P, Neubauer, A, Damaj, G, Koc, Y, Ganser, A, Collin, M, Yakoub-Agha, I, Ozdogu, H, Araujo, MC, Itala-Remes, M, Orchard, K, Isaksson, C, Bethge, W, Martin, H, Aljurf, M, Faber, E, Caballero, D, Zak, P, Leleu, X, Bay, JO, Rohrlich, PS, Kroger, N, Huynh, A, Schafer-Eckart, K, Milpied, N, Lenhoff, S, Ho, A, Lopez, JLB, Mordini, N, Lioure, B, Halaburda, K, Olivieri, A, Gedde-Dahl, T, Protheroe, R, Tischer, J, Klammer, M, Clausen, J, Potter, V, Ladetto, M, Tilly, H, Deconinck, E, Brecht, A, Muller, LP, Heinicke, T, Carrete, JPT, Bazarbachi, A, Remenyi, P, Rubio, MT, Fanin, R, Perez-Simon, JA, Niels, M, Diez-Martin, JL, Arat, M, Hermine, O, Socie, G, Cornelissen, JJ, Santarone, S, Guyotat, D, Bulabois, CE, Bernasconi, P, Johansson, JE, Vrhovac, R, Greinix, H, Lorenzo, JLL, Apte, S, Craddock, C, Kobbe, G, Zahrani, MA, Dreger, P, Lange, A, Tbakhi, A, Meijer, E, Llamas, CV, Santasusana, JMR, Corradini, P, Benedetti, F, Rambaldi, A, Gandemer, V, Malfuson, JV, Kaare, A, Risitano, A, Petrini, M, Selleri, C, Wu, DP

Publikováno v: Bone Marrow Transplantation
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

The optimal conditioning for patients with acute myeloid leukemia in first complete remission treated with allogeneic hematopoietic cell transplantation (allo-HCT) has not been defined so far. In this retrospective study, we compared two "reduced-tox

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::3648997c04fa97d9f102964f774d16ce
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4419

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Autor: Attal, M. Richardson, P.G. Rajkumar, S.V. San-Miguel, J. Beksac, M. Spicka, I. Leleu, X. Schjesvold, F. Moreau, P. Dimopoulos, M.A. Huang, J.S.-Y. Minarik, J. Cavo, M. Prince, H.M. Macé, S. Corzo, K.P. Campana, F. Le-Guennec, S. Dubin, F. Anderson, K.C. Richardson, P.G. Rajkumar, V. Dimopoulos, M.A. Corzo, K.P. Harrison, S. Janowski, W. Kerridge, I. Spencer, A. Delforge, M. Fostier, K. Vlummens, P. Wu, K.L. Leblanc, R. Pavic, M. Sebag, M. Hajek, R. Maisnar, V. Pour, L. Gregersen, H. Benbouker, L. Caillot, D. Escoffre-Barbe, M. Facon, T. Frenzel, L. Hulin, C. Karlin, L. Kolb, B. Pegourie, B. Perrot, A. Tiab, M. Vincent, L. Niederwieser, D. Anagnostopoulos, A. Delimpasi, S. Kyrtsonis, M.-C. Symeonidis, A. Illes, A. Mikala, G. Nagy, Z. Bringen, S. Corradini, P. Fabio, C. Lemoli, R. Liberati, A. Nozzoli, C. Zambello, R. Iida, S. Ikeda, T. Iyama, S. Matsumoto, M. Shimazaki, C. Sunami, K. Suzuki, K. Uchiyama, M. Koh, Y. Kim, K. Lee, J.H. Min, C.-K. Blacklock, H. Goodman, H. Neylon, A. Simpson, D. Grosicki, S. Jurczyszyn, A. Walter-Croneck, A. Warzocha, K. Araujo, L. Moreira, C. Doronin, V. Mendeleeva, L. Vorobyev, V. Vranovsky, A. Alegre, A. Gironella, M. Gonzalez Perez, M.S. Montes, C. Ocio, E. Rodriguez, P. Hardling, M. Lauri, B. Wang, M.-C. Yeh, S.-P. Arat, M. Demirkan, F. Gulbas, Z. Besisik, S.K. Karadogan, I. Tuglular, T. Unal, A. Vural, F. Sive, J. Streetly, M. Yong, K. Tache, J.

Background: Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::d9c2f582489791b10d9d97a07b2ad870
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3121675

experience

Autor: Bekoz, H, Karadurmus, N, Paydas, S, Turker, A, Toptas, T, Tuglular, TF, Sonmez, M, Gulbas, Z, Tekgunduz, E, Kaya, AH, Ozbalak, M, Tastemir, N, Kaynar, L, Yildirim, R, Karadogan, I, Arat, M, Tanrikulu, FP, Ozkocaman, V, Abali, H, Turgut, M, Yuksel, MK, Ozcan, M, Dogu, MH, Hacioglu, SK, Barista, I, Demirkaya, M, Koseoglu, FD, Toprak, SK, Yilmaz, M, Demirkurek, HC, Demirkol, O, Ferhanoglu, B

Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::41a93b1efc07a4e851ef608091a28bf9
http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/15718

A long-term survival pattern for breast cancer treated in a single institution.

Autor: Gokce, T.^1,2 tcgokce@gmail.com, Karadogan, I.², Akçay, C.²

Publikováno v: Indian Journal of Cancer. Apr-Jun2011, Vol. 48 Issue 2, p187-193. 7p. 4 Charts, 1 Graph.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.